Canada Markets closed

PharmaTher Holdings Ltd. (PHRRF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2700-0.0050 (-1.82%)
At close: 03:38PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.3089
Open0.2960
BidN/A x N/A
AskN/A x N/A
Day's Range0.2815 - 0.3005
52 Week Range0.1400 - 1.3900
Volume126,266
Avg. Volume539,231
Market Cap18.64M
Beta (5Y Monthly)N/A
PE Ratio (TTM)8.71
EPS (TTM)0.0310
Earnings DateOct. 27, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

    TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the development and commercialization of specialty ketamine prescription-based products, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted an investigator-initiated investigational new drug ("IND") application to proceed with a Phase 2 clinical trial (the “Study”) evaluating ketamine in the treatment of Amyotrophic Late

  • GlobeNewswire

    PharmaTher Announces Publication of Research Data for KETABET™

    Second published study to demonstrate the potential therapeutic utility and mechanism of action of KETABET™ (patented combination of ketamine and betaine) in models of depression Repeated use of KETABET™ exhibits potential protective and reversing effects on ketamine-elicited psychotomimetic behaviors and cognitive impairments Supports clinical initiatives as a potential next generation ketamine treatment for mental health and pain disorders with patent protection into 2036 TORONTO, Jan. 04, 202

  • GlobeNewswire

    PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

    Focused on becoming a leader in the development and commercialization of specialty ketamine prescription-based products Expected milestones for 2022 include initiating Phase 3 clinical study for ketamine to treat Parkinson’s disease (KETLID); completing Phase 2 clinical study for ketamine to treat ALS (KETALS); completing observational study with ketamine and betaine for depression and pain (KETABET); initiating Phase 2 clinical study for ketamine microneedle patch (KETAPATCH); and seeking FDA a